A Cost-Effectiveness and Cost-Benefit Analysis of Contingency Contracting–Enhanced Methadone Detoxification Treatment

REFERENCES

• French M., Rachal J., Hubbard R. Conceptual framework for estimating the social cost of drug abuse. J. Health Soc. Policy 1991; 2: 1–22
   PubMedGoogle Scholar
• Rice D., Kelman S., Miller L. Economic costs of drug abuse. Economic Costs, Cost-Effectiveness, Financing, and Community-Based Drug Treatment, NIDA Research Monograph 113, U.S. Government Printing Office, Rockville, Maryland, 1991, pp. 10–32
   Google Scholar
• Yates B. Cost-effectiveness analysis and cost-benefit analysis: An introduction. Behav. Assess 1985; 7: 207–234
   Google Scholar
• Harwood H. Economics and drugs: Promises, problems, and prospects. Economic Costs, Cost-Effectiveness, Financing, and Community-Based Drug Treatment, NIDA Research Monograph 113, U.S. Government Printing Office, Rockville, Maryland, 1991, pp. 46–56
   Google Scholar
• Jerrell J., Hu T., Ridgely M. Cost-effectiveness of substance disorder interventions for people with severe mental illness. J. Ment. Health Adm 1994; 21: 283–297
   PubMedGoogle Scholar
• Center on Addictions and Substance Abuse at Columbia University. Substance Abuse and Urban America: Its Impact on an American City, New York. Center on Addictions and Substance Abuse at Columbia University, New York 1996
   Google Scholar
• Harwood H., Hubbard R., Collins J., et al. The costs of crime and the benefits of drug abuse treatment: A cost-benefit analysis using TOPS data. Compulsory Treatment of Drug Abuse: Research and Clinical Practice, NIDA Research Monograph 86, U.S. Government Printing Office, Rockville, Maryland, 1988, pp. 209–235
   Google Scholar
• Hubbard R., Marsden M., Rachal J., et al. Drug Abuse Treatment: A National Study of Effectiveness. The University of North Carolina Press, Chapel Hill 1989
   Google Scholar
• Tabbush V. The Effectiveness and Efficiency of Publicly Funded Drug Abuse Treatment and Prevention Programs in California: A Benefit-Cost Analysis. Economic Analysis Corporation, Los Angeles 1986
   Google Scholar
• Yates B. Toward the incorporation of costs, cost-effectiveness analysis, and cost-benefit analysis into clinical research. J. Consult. Clin. Psychol. 1994; 62: 729–736
   PubMed Web of Science ®Google Scholar
• French M. Economic evaluation of drug abuse treatment programs: Methodology and findings. Am. J. Drug Alcohol Abuse 1995; 21: 111–135
   PubMed Web of Science ®Google Scholar
• Bradley C., French M., Rachal J. Financing and cost of standard and enhanced methadone treatment. J. Substance Abuse Treat. 1994; 11: 433–442
   PubMed Web of Science ®Google Scholar
• McLellan A., Kushner H., Metzger D., et al. The Fifth Edition of the Addiction Severity Index. J. Substance Abuse Treat. 1992; 9: 199–213
   PubMed Web of Science ®Google Scholar
• Hubbard R., French M. New perspectives on the benefit-cost and cost-effectiveness of drug abuse treatment. Economic Costs, Cost-Effectiveness, Financing, and Community-Based Drug Treatment, NIDA Research Monograph 113, U.S. Government Printing Office Rockville, Maryland, 1991, pp. 94–113
   Google Scholar
• Yates B. Cost-effectiveness analysis, cost-benefit analysis, and beyond: Evolving models of the scientist/manager/practitioner. Clin. Psychol. Sci. Pract 1995; 2: 385–398
   Web of Science ®Google Scholar
• Apsler R. Evaluating the cost-effectiveness of drug abuse treatment services. Economic Costs, Cost-Effectiveness, Financing, and Community-Based Drug Treatment, NIDA Research Monograph 113, U.S. Government Printing Office, Rockville, Maryland, 1991, pp. 57–66
   Google Scholar
• Hall S. M., Clark H. W., Sees K. L. Drug abuse, drug treatment, and public policy. Drug Policy and Human Nature: Psychological Perspectives on the Control, Prevention and Treatment of Illicit Drug Use, W. K. Bickel, R. J. De Grandpre. Plenum, New York 1995
   Google Scholar
• Piotrowski N. A., Hall S. M. Intensive psychosocial treatment with and without contingency management procedures in a methadone clinic. Motivating Behavioral Change Among Illicit Drug Abusers: Contemporary Research on Contingency Management Interventions, S. T. Higgins, K. Silverman. American Psychological Association Press. 1999; 183–202
   Google Scholar
• Reilly P., Banys P., Tusel D., et al. Methadone transition treatment: A model for 180-day methadone detoxification. Int. J. Addict. 1995; 30: 387–402
   PubMed Web of Science ®Google Scholar
• Higgins S., Stitzer M., Bigelow G., et al. Contingent methadone delivery: Effects on illicit opiate use. Drug Alcohol Depend. 1986; 17: 311–312
   PubMed Web of Science ®Google Scholar
• Silverman K., Higgins S., Brooner R., et al. Differential reinforcement of sustained cocaine abstinence in intravenous polydrug abusers. in Problems on Drug Dependence 1994: Proceedings of the 56th Annual Scientific Meeting, NIDA Research Monograph 153, U.S. Government Printing Office, Rockville, Maryland, 1995, p. 212
   Google Scholar
• Ellison J., Blum N., Barsky A. Frequent repeaters in a psychiatric emergency service. Hosp. Community Psychiatry 1989; 40: 958–960
   PubMedGoogle Scholar
• Purdie F., Honigman B., Rosen P. The chronic emergency department patient. Ann. Emerg. Med. 1981; 10: 298–301
   PubMed Web of Science ®Google Scholar
• Seage G., Hertz T., Stone V., et al. The effects of intravenous drug use and gender on the cost of hospitalization for patients with AIDS. J. Acquir. Immune Defic. Syndr. 1993; 6: 831–839
   PubMed Web of Science ®Google Scholar
• Slaby A., Perry P. Use and abuse of psychiatric emergency services. Int. J. Psychiatry Med. 1980; 10: 1–8
   PubMed Web of Science ®Google Scholar
• Sullivan P., Bulik C., Forman S., et al. Characteristics of repeat users of a psychiatric emergency service. Hosp. Community Psychiatry 1993; 44: 376–380
   PubMedGoogle Scholar